Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy-Reference-Cited by-同舟云学术

Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy

Published:2019-05-02 Issue:6 Volume:33 Page:593-604
ISSN:1172-7047
Container-title:CNS Drugs
language:en
Short-container-title:CNS Drugs

Author:

Wheless James W.,Dlugos Dennis,Miller Ian,Oh D. Alexander,Parikh Neha,Phillips Steven,Renfroe J. Ben,Roberts Colin M.,Saeed Isra,Sparagana Steven P.,Yu Jin,Cilio Maria Roberta^ORCID,

Funder

Insys

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Psychiatry and Mental health,Clinical Neurology

Link

https://link.springer.com/content/pdf/10.1007/s40263-019-00624-4.pdf

Reference28 articles.

1. Russ SA, Larson K, Halfon N. A national profile of childhood epilepsy and seizure disorder. Pediatrics. 2012;129(2):256–64.

2. Ostendorf AP, Ng YT. Treatment-resistant Lennox–Gastaut syndrome: therapeutic trends, challenges and future directions. Neuropsychiatr Dis Treat. 2017;13:1131–40.

3. Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551–63.